A wide field survey at the Northern Ecliptic Pole: II. Number counts and galaxy colours in B_j, R, and K

We present a medium deep survey carried out in the three filters B_j, R and K. The survey covers homogeneously the central square degree around the Northern Ecliptic Pole (NEP) down to a completeness limit of 24.25, 23.0 and 17.5mag in B_j, R and K, respectively. While the near infrared data have been presented in the first paper of this series, here we concentrate on the optical data and the results based on the combined B_jRK-data. The unique combination of area and depth in our survey allows to perform a variety of investigations based on homogeneous material covering more than ten magnitudes in apparent brightness. We analyze the number counts for point-like and extended sources in B_j and R to determine the slopes in dlogN/dm and to test for possible breaks therein. While we can confirm the slopes found in previous works with a higher statistical significance, the largest uncertainty remaining for the amplitudes is galactic extinction. We determine the colour distributions of galaxies in B_j-R and R-K down to B_j=24.0 and K=18.0mag, respectively. The distributions in both colours are modeled using galaxy spectral evolution synthesis. We demonstrate that the standard models of galaxy evolution are unable to reproduce the steady reddening trend in R-K despite flawless fits to the colour distributions in the optical (B_j-R). The B_jRK data collected over a large area provides the opportunity to select rare objects like candidates for high-redshift galaxies and extremely red objects (EROs, R-K>5.0) and to determine their surface density. Our EROs are selected at an intermediate magnitude range and contain contribution from both galactic as well as extragalactic sources. At K<16.5mag, where a morphological classification is possible, the stellar component dominates the sample.Comment: Accepted for A&A, 14 pages, 10 figure

Characterization of the self-palmitoylation activity of the transport protein particle component Bet3

Bet3, a transport protein particle component involved in vesicular trafficking, contains a hydrophobic tunnel occupied by a fatty acid linked to cysteine 68. We reported that Bet3 has a unique self-palmitoylating activity. Here we show that mutation of arginine 67 reduced self-palmitoylation of Bet3, but the effect was compensated by increasing the pH. Thus, arginine helps to deprotonate cysteine such that it could function as a nucleophile in the acylation reaction which is supported by the structural analysis of non-acylated Bet3. Using fluorescence spectroscopy we show that long-chain acyl-CoAs bind with micromolar affinity to Bet3, whereas shorter-chain acyl-CoAs do not interact. Mutants with a deleted acylation site or a blocked tunnel bind to Pal-CoA, only the latter with slightly reduced affinity. Bet3 contains three binding sites for Pal-CoA, but their number was reduced to two in the mutant with an obstructed tunnel, indicating that Bet3 contains binding sites on its surface

The WFC3 Infrared Spectroscopic Parallel (WISP) Survey

We present the WFC3 Infrared Spectroscopic Parallel (WISP) Survey. WISP is obtaining slitless, near-infrared grism spectroscopy of ~ 90 independent, high-latitude fields by observing in the pure parallel mode with Wide Field Camera-3 on the Hubble Space Telescope for a total of ~ 250 orbits. Spectra are obtained with the G102 (lambda=0.8-1.17 microns, R ~ 210) and G141 grisms (lambda=1.11-1.67 microns, R ~ 130), together with direct imaging in the J- and H-bands (F110W and F140W, respectively). In the present paper, we present the first results from 19 WISP fields, covering approximately 63 square arc minutes. For typical exposure times (~ 6400 sec in G102 and ~ 2700 sec in G141), we reach 5-sigma detection limits for emission lines of 5 x 10^(-17) ergs s^(-1) cm^(-2) for compact objects. Typical direct imaging 5sigma-limits are 26.8 and 25.0 magnitudes (AB) in F110W and F140W, respectively. Restricting ourselves to the lines measured with highest confidence, we present a list of 328 emission lines, in 229 objects, in a redshift range 0.3 < z < 3. The single-line emitters are likely to be a mix of Halpha and [OIII]5007,4959 A, with Halpha predominating. The overall surface density of high-confidence emission-line objects in our sample is approximately 4 per arcmin^(2).These first fields show high equivalent width sources, AGN, and post starburst galaxies. The median observed star formation rate of our Halpha selected sample is 4 Msol/year. At intermediate redshifts, we detect emission lines in galaxies as faint as H_140 ~ 25, or M_R < -19, and are sensitive to star formation rates down to less than 1 Msol/year. The slitless grisms on WFC3 provide a unique opportunity to study the spectral properties of galaxies much fainter than L* at the peak of the galaxy assembly epoch.Comment: 15 pages, 12 figures, submitted to Ap

Feasibility studies of the time-like proton electromagnetic form factor measurements with PANDA at FAIR

The possibility of measuring the proton electromagnetic form factors in the time-like region at FAIR with the \PANDA detector is discussed. Detailed simulations on signal efficiency for the annihilation of $\bar p +p$ into a lepton pair as well as for the most important background channels have been performed. It is shown that precision measurements of the differential cross section of the reaction $\bar p +p \to e^++ e^-$ can be obtained in a wide angular and kinematical range. The individual determination of the moduli of the electric and magnetic proton form factors will be possible up to a value of momentum transfer squared of $q^2\simeq 14$ (GeV/c)$^2$. The total $\bar p +p\to e^++e^-$ cross section will be measured up to $q^2\simeq 28$ (GeV/c)$^2$. The results obtained from simulated events are compared to the existing data. Sensitivity to the two photons exchange mechanism is also investigated.Comment: 12 pages, 4 tables, 8 figures Revised, added details on simulations, 4 tables, 9 figure

DNA Methylation of the ABO Promoter Underlies Loss of ABO Allelic Expression in a Significant Proportion of Leukemic Patients

Background: Loss of A, B and H antigens from the red blood cells of patients with myeloid malignancies is a frequent occurrence. Previously, we have reported alterations in ABH antigens on the red blood cells of 55% of patients with myeloid malignancies. Methodology/Principal Findings: To determine the underlying molecular mechanisms of this loss, we assessed ABO allelic expression in 21 patients with ABH antigen loss previously identified by flow cytometric analysis as well as an additional 7 patients detected with ABH antigen changes by serology. When assessing ABO mRNA allelic expression, 6/12 (50%) patients with ABH antigen loss detected by flow cytometry and 5/7 (71%) of the patients with ABH antigen loss detected by serology had a corresponding ABO mRNA allelic loss of expression. We examined the ABO locus for copy number and DNA methylation alterations in 21 patients, 11 with loss of expression of one or both ABO alleles, and 10 patients with no detectable allelic loss of ABO mRNA expression. No loss of heterozygosity (LOH) at the ABO locus was observed in these patients. However in 8/11 (73%) patients with loss of ABO allelic expression, the ABO promoter was methylated compared with 2/10 (20%) of patients with no ABO allelic expression loss (P = 0.03). Conclusions/Significance: We have found that loss of ABH antigens in patients with hematological malignancies is associated with a corresponding loss of ABO allelic expression in a significant proportion of patients. Loss of ABO allelic expression was strongly associated with DNA methylation of the ABO promoter.Tina Bianco-Miotto, Damian J. Hussey, Tanya K. Day, Denise S. O'Keefe and Alexander Dobrovi

Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic

Many patients with ER+ HER2- primary breast cancer are being deferred from surgery to neoadjuvant endocrine therapy (NeoET) during the COVID-19 pandemic. We have collated data from multiple international trials of presurgical endocrine therapy in order to provide guidance on the identification of patients who may have insufficiently endocrine-sensitive tumors and should be prioritised for early surgery or neoadjuvant chemotherapy rather than NeoET during or in the aftermath of the COVID-19 pandemic for safety or when surgical activity needs to be prioritized. For postmenopausal patients, our data provide strong support for the use of ER and PgR status at diagnosis for triaging of patients into three groups in which (taking into account clinical factors): (i) NeoET is likely to be inappropriate (Allred ER 10%) indicates a higher priority for early surgery. Too few data were available for premenopausal patients to provide a similar treatment algorithm. These guidelines should be helpful for managing patients with early ER+ HER2- breast cancer during and in the aftermath of the COVID-19 crisis